Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in Biochem Biophys Res Commun

Retrieve available abstracts of 7 articles:
HTML format

Single Articles

    March 2022
  1. XU N, Yang XF, Xue SL, Tan JW, et al
    Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells.
    Biochem Biophys Res Commun. 2022;595:54-61.
    PubMed     Abstract available

    January 2021
  2. NOZAWA T, Mihara-Tomiyama N, Chiba T, Imai K, et al
    NF-kappaB subunit RELA suppression of mucosa-associated lymphoid tissue lymphoma translocation protein 1 expression in oral carcinoma cells.
    Biochem Biophys Res Commun. 2021;542:24-28.
    PubMed     Abstract available

    December 2020
  3. LIANG Z, Qin Z, Riker AI, Xi Y, et al
    CRISPR/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus.
    Biochem Biophys Res Commun. 2020;533:1400-1405.
    PubMed     Abstract available

    November 2020
  4. WATTERS JM, Wright G, Smith MA, Shah B, et al
    Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.
    Biochem Biophys Res Commun. 2020 Nov 12. pii: S0006-291X(20)32044.
    PubMed     Abstract available

    June 2020
  5. LEE SH, Lee HT, Lim H, Kim Y, et al
    Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
    Biochem Biophys Res Commun. 2020;527:226-231.
    PubMed     Abstract available

  6. SHIMOSAKI S, Nakahata S, Ichikawa T, Kitanaka A, et al
    Corrigendum to "Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma [Biochem. Biophys. Res. Commun. 485 (1) 2017 144-151].
    Biochem Biophys Res Commun. 2020 Jun 15. pii: S0006-291X(20)31076.

    May 2020
  7. JEONG S, Sohn YK, Choi Y, Park J, et al
    A regulatory SH2 domain-targeting protein binder effectively inhibits the activity of Bruton's tyrosine kinase and its drug-resistant variants.
    Biochem Biophys Res Commun. 2020;526:8-13.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.